Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Anika Therapeutics (ANIK) stocks in Canada

Learn how to easily invest in Anika Therapeutics stocks.

Anika Therapeutics is a medical devices business based in the US. Anika Therapeutics stocks (ANIK.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.74 – a decrease of 1.53% over the previous week. Anika Therapeutics employs 277 staff and has a trailing 12-month revenue of around $144.7 million.

How to buy shares in Anika Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANIK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Anika Therapeutics stock price (NASDAQ:ANIK)

Use our graph to track the performance of ANIK stocks over time.

Anika Therapeutics shares at a glance

Information last updated 2022-01-25.
Latest market close$31.50
52-week range$31.20 - $48.37
50-day moving average $37.45
200-day moving average $40.80
Wall St. target price$50.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.40

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Anika Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Anika Therapeutics price performance over time

Historical closes compared with the close of $31.5 from 2022-01-27

1 week (2022-01-21) -1.53%
1 month (2021-12-29) -14.61%
3 months (2021-10-27) -23.75%
6 months (2021-07-29) -23.41%
1 year (2021-01-29) -14.89%
2 years (2020-01-28) -30.33%
3 years (2019-01-28) 37.05
5 years (2017-01-27) 50.13

Is Anika Therapeutics under- or over-valued?

Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Anika Therapeutics's PEG ratio

Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1868. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Anika Therapeutics's EBITDA

Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.4 million.

The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.

Anika Therapeutics financials

Revenue TTM $144.7 million
Gross profit TTM $80.1 million
Return on assets TTM -0.93%
Return on equity TTM -1.99%
Profit margin -3.96%
Book value $20.09
Market capitalisation $475 million

TTM: trailing 12 months

Anika Therapeutics share dividends

We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.

Anika Therapeutics share price volatility

Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $31.2 up to $48.37. A popular way to gauge a stock's volatility is its "beta".

ANIK.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 1.1242. This would suggest that Anika Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Anika Therapeutics overview

Anika Therapeutics, Inc. , together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Stocks similar to Anika Therapeutics

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site